Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
- PMID: 26124479
- DOI: 10.1200/JCO.2015.61.0576
Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?
Comment in
-
Reply to M.G. McNamara et al and M.S. Copur et al.J Clin Oncol. 2015 Aug 10;33(23):2583-4. doi: 10.1200/JCO.2015.61.8298. Epub 2015 Jun 29. J Clin Oncol. 2015. PMID: 26124483 No abstract available.
Comment on
-
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3. J Clin Oncol. 2015. PMID: 25366685 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
